| Metric | Value (₹ Cr) | Q1 FY27 | Q2 FY26 |
|---|---|---|---|
| Revenue | 486.99 | 18.6% | 19.2% |
| Total Income | 495.08 | 17.0% | 18.8% |
| Expenditure | 395.22 | 12.0% | 24.2% |
| PBT | 99.86 | 41.6% | 1.5% |
| Net Profit | 75.09 | 42.5% | 2.6% |
| OPM | 31.11% | 3.18pp | 3.34pp |
| NPM | 15.17% | 2.72pp | 2.39pp |
| EPS | 7.41 | 42.5% | 2.9% |
Detailed report is being prepared.
Growth momentum meets capacity ramp — can margins hold as expansion accelerates?
Rainbow Children's Medicare enters Q2 on a 33% YoY growth run with three hospitals newly operational. Analysts expect the expansion playbook to sustain momentum, but watch EBITDA margins as the company absorbs start-up costs and new facility ramp-up.
What to Expect
Rainbow Children's Medicare enters Q2 FY27 off a strong Q1 — 33% YoY revenue growth to ₹4,700 Cr, EBITDA up 30% to ₹1,346 Cr. The company targets 24–25% EBITDA margins for FY27–FY28 and a 20% revenue CAGR over four years. On that trajectory, Q2 FY27 revenue is on-plan to reach ~₹5,800–6,100 Cr (a 25–30% YoY increase from ₹4,600 Cr in Q2 FY26).
~₹5,800–6,100 Cr
25–30% YoY growth from Q2 FY26 base (₹4,600 Cr); driven by base hospital maturity + new capacity (Guntur, Malad, acquired units)
24–25%
Per FY27–FY28 guidance; watch for start-up drag from newly operational hospitals and acquisition integration
~3,725 beds by FY29
Malad (100 beds) expected operational by Q2 FY27; Guntur (50 beds) now live; 64% stake in Super Prime adds immediate footprint
₹1,682
14-analyst consensus Strong Buy; 44% upside from Oct 23 price of ₹1,170; implies 26% EPS growth to ₹30.28 for FY27
A strong print would show EBITDA margins maintaining the 24–25% band despite the expense of ramp-up, signaling operational discipline as new facilities scale. A weak print would see margins compress below 24% — a sign that start-up costs and the acquisition integration are heavier than expected, or that growth is pulling capital allocation away from profitability.
Is the Company On Track?
Yes, on the growth and guidance trajectory. Q1 FY27's 33% YoY growth is above the 20% CAGR target, and the company's expansion playbook (Guntur operational, Malad on track, acquisition closed) is executing on plan. The real test: whether EBITDA margins hold at 24–25% as the company absorbs three simultaneous growth drivers — new hospitals ramping, the acquired entity integrating, and organic base hospital growth. Management transition (CFO Sudarshan Patodia appointed Sep 23) adds execution risk, though the appointment was approved by the board and the company stated no material change to guidance.
What the Street Says
Since Last Quarter — Recent Filings & Updates
1 · Guntur Hospital Now Operational (Sep 16)
50-bed women's and children's hospital in Andhra Pradesh commenced operations. This represents the first material new hospital addition in FY27; ramp trajectory and volume absorption will be a key metric in Q2 and beyond.
2 · Super Prime Medical Care Acquisition Completed (Aug 14)
Rainbow Children's Medicare finalized acquisition of 64% partnership interest in Super Prime Medical Care LLP for ₹19.84 Cr. Integration costs and accounting treatment will affect Q2 consolidated numbers; watch for one-off charges or step-ups in depreciation.
3 · CFO Transition: Vikas Maheshwari → Sudarshan Patodia (Aug 25 – Sep 23)
Vikas Maheshwari (CFO) resigned Aug 31; Sudarshan Patodia appointed CFO and Group CFO on Sep 23. Board approval and no material guidance change, but transition risk during expansion phase warrants monitoring.
4 · Amaravati Land Lease Signed (Sep 30)
Executed 60-year lease with APCRDA for ~2 acres in Amaravati (AP capital). Strategic land bank for greenfield expansion; no immediate revenue impact, but signals long-term capacity planning in tier-2 geographies.
5 · ESOP Grants — Sep 23 & Jul 30
Granted 55,690 stock options (Sep 23) + 2,570 options to CLO Anshuman Jaiswal (Jul 30). Routine management retention, no material P&L impact.
6 · Mumbai Expansion: 100-Bed Facility for ₹90 Cr (Jul 29)
New 100-bed children's hospital in Mumbai via subsidiary Rainbow Women & Children's Hospital Private Limited (RWCHPL). Significant capex; Malad facility expected operational by Q2 FY27 per guidance.
Pledges, insider activity, or regulatory flags: None flagged in the filings since Q1 results. FII outflow trend (down 7.6pp YoY) is structural, not event-driven.
The Setup
Rainbow Children's Medicare is firing on growth — 33% YoY in Q1, new capacity live, major acquisition closed, and a 20% revenue CAGR roadmap backed by analyst conviction (Strong Buy, ₹1,682 target). But the stock is down 31% from ATH, and the real debate is whether margins hold as three growth engines (new hospitals, acquisition, organic) all rev up at once. Q2 FY27 will be the first hard test: expect revenue to land in the ₹5,800–6,100 Cr range (25–30% YoY growth) and EBITDA margin to stay in the 24–25% band. Watch three things on Oct 31: (1) EBITDA margin hold — any breach of 24% signals execution drag; (2) New hospital ramp visibility — Guntur and Malad occupancy, bed count, revenue contribution; (3) FY27 guidance reaffirmation — any margin downgrade or capex repricing could reignite the FII selloff that's driven the 31% drawdown.